Table 2.
Baseline characteristics of VTE patients (N = 13; 11.6%).
| Characteristic | Value | Percentage |
|---|---|---|
| Median age at study entry (years) | 67 | |
| IQR | 62–71 | |
| Sex | ||
| Female | 2 | 15% |
| Male | 11 | 85% |
| Site of cancer | ||
| Rectum | 6 | 46% |
| Rectosigmoid junction | 0 | 0 |
| Sigmoid colon | 2 | 15% |
| Splenic flexure | 1 | 7.7% |
| Transverse colon | 1 | 7.7% |
| Hepatic flexure | 0 | 0 |
| Ascending colon | 1 | 7.7% |
| Cecum | 2 | 0,15 |
| Appendix | 0 | 0 |
| Two sites | 0 | 0 |
| Unknown | 0 | 0 |
| Tumor stage at study entry | ||
| Stage 0 | 0 | 0 |
| Stage I | 1 | 7.7% |
| Stage II | 1 | 7.7% |
| Stage III | 3 | 23% |
| Stage IV | 8 | 62% |
| Progression of tumor at study entry* | ||
| Localized | 5 | 38% |
| Distant metastasis | 8 | 62% |
| Tumor stage when VTE occurred | ||
| Stage 0 | 0 | 0% |
| Stage I | 0 | 0% |
| Stage II | 0 | 0% |
| Stage III | 2 | 15% |
| Stage IV | 11 | 85% |
| Anti-VEGF-A treatment and VTE | ||
| Bevacizumab at time of VTE (+4 weeks) | 4 | 31% |
| In relation to total population with bevacizumab | 4 | 8.2% |
| Site of thrombotic event counted | ||
| Isolated pulmonary vein thrombosis (PE) | 6 | 46% |
| Isolated deep vein thrombosis (DVT) | 6 | 46% |
| Subclavian vein thrombosis (PAC-implant) | 1 | 7.7% |
Categorical variables are described with absolute numbers and percentages. Age is described as median with IQR.
*
For staging UICC staging was used (stage Ia and Ib are summarized as stage I; stage 0 is defined as ypT0pN0M0, R0 - these are patients with rectum carcinoma, who received presurgical radiotherapy).